47 Rue Adrienne Bolland
Ncardia's expertise in MEA assays enables us to study the cardiac safety profile of your compounds at an early stage of drug development, using the Maestro MEA system.
Investigating the electrical activity of human induced pluripotent stem cell-derived cardiomycoytes and their acute response to drugs is part of the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative*, which aims to refine current ICH guidelines to predict clinical potential for life threatening Torsade de Pointes (TdP) tachyarrhythmia. Ncardia is an official partner of the CiPA initiative and our cardiomyocytes were implemented by different core and non-core test sites.
The acute cardiac safety assessment is performed using pre-plated iPSC-derived cardiomyocytes in the Ncyte Cardioplate Maestro MEA. This guarantees a fully controlled assay plate with high plate-to-plate reproducibility. Combined with with MEA platforms, this provides a highly relevant and predictive in vitro assay platform to study compounds’ cardiac safety profile in drug development.
*CiPA (Comprehensive in Vitro Proarrhythmia Assay) is a project driven by the Health and Environmental Science Institute (HESI) and the FDA.
Would you like to know more about our acute cardiac safety service, or any of our other services?
We're here to listen to your project plans, questions and challenges, and to co-develop a solution that fits your specifications. Please leave your details and message in the form below and we will get back to you as soon as possible.